DOCSLIB.ORG

Bacillary Dysentery and Amebic Dysentery

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Bacillary Dysentery and Amebic Dysentery King Saud University College of Medicine GIT BLOCK 2nd Year, 2nd Block L3: Treatment of dysentery and amebiasis Learning objectives . To understand different causes of dysentery. To describe different classes of drugs used in treatment of both bacillary dysentery and amebic dysentery. To be able to describe actions, side effects of drugs for treating bacillary dysentery. To understand the pharmacokinetics, actions, clinical applications and side effects of antiamebic drugs. To be able to differentiate between types of antiamebic drugs; luminal amebicides, and tissue amebicide. slide doctor’s note important explanation slide doctor’s note important explanation Dysentery Causes: 1- viral infection Treatment : 2- bacterial infection -Maintain fluid intake using 3-parasitic infestations Definition : oral rehydration (due to The two most common sever diarrhea) therapy or is an inflammatory causes are: I.V fluid therapy. disorder of the intestine -Amebic dysentery Antimicrobial agents should (colon), that results in (protozoal infection mainly not be given until stool severe diarrhea by Entameba Histolytica). analysis is done (emperic containing mucus and/or therapy should be started blood in the feces with -Bacillary dysentery after sample of stool taken fever and abdominal (or shigellosis) (bacterial for analysis). After stool pain. infection mainly by shigella). results & detecting the pathogen we give more specific drugs. slide doctor’s note important explanation Amoebiasis Definition Clinical presentation • Amebiasis is a protozoal • Asymptomatic intestinal infection infection of the intestinal (Carriers, passing cysts in stool) tract that occurs due to • Mild to moderate intestinal disease ingestion of foods or water (colitis) contaminated with cysts of • Severe intestinal infection (amoebic Entameba Histolytica. dysentery) present sometimes with blood and mucus. • The patients show varying • Ameboma (localized degree of illness from no granulomatous lesion of colon). symptoms to mild diarrhea • Hepatic abscess, and other extra- to severe dysentery. intestinal diseases. slide doctor’s note important explanation LIFE CYCLE Cysts ingestion in contaminated food or water Cyst formation Liberation of in rectum and trophozoites in excretion in the colon feces Systemic invasion to Invasion of other organs intestinal wall (liver, lungs, brain). Multiplication of trophozoites within colon wall slide doctor’s note important explanation *after we finish from systemic amebicides Antiamebic Drugs treatment we have to follow the Luminal Amebicides treatment to clear the Lumen A-Tissue or systemic B-Luminal Amebicides amebicides* Act on ameba in tissues Acts on the parasites in the lumen e.g. the intestinal wall and/or other of the bowel. (non-systemic) extra-intestinal tissues as liver, brain and lung. Action Used for treatment of systemic form of used for treatment of asymptomatic the disease (invasive amebiasis) e.g. amebiasis (carriers). intestinal wall infection or liver uses abscesses. 1.Metronidazole Diloxanide furoate 2.Emetine Iodoquinol 3.Dehydroemetine 4.Chloroquine (liver only) Paromomycin include slide doctor’s note important explanation 1. Metronidazole Metronidazole Pharmacokinetics Clinical Uses -Tissue ameobicide. Given orally or IV. 1-Extra-luminal amoebiasis: is -Acts on trophozoites. Absorption is rapid and complete. the drug of choice in all tissue -inhibits DNA Wide distribution to all tissues and amebiasis replication. body fluids (CSF, saliva, milk). (should be followed by -Does not eradicate cysts luminal amebicides) to get rid off Plasma half life is (8 h) from intestine. pathogens from tissue + lumen (not Metabolized in liver by mixed becoming a carrier) -Drug of choice for function oxidase* followed by 2-Giardiasis treating invasive amebic glucuronidation (consider drug 3-Trichomoniasis infections (intestinal & interactions). 4-Broad spectrum of extra-intestinal anaerobic bacterial infections amebiasis) Excreted in urine. e.g. Clearance is decreased in liver Peptic ulcer (Helicobacter impairment pylori) Pseudo-membranous colitis *Cytochrome p450 (Clostridium difficile). Dental infection slide doctor’s note important explanation 1. Metronidazole Adverse affects Drug interactions CONTRAINDICATIONS *GIT: .Enzyme inhibitors *Pregnancy and breast Dry mouth, metallic taste, Nausea, vomiting, diarrhea (cimetidine, ketoconazole) feeding women. (NVD), Oral Thrush (Moniliasis, * Alcohol intake. yeast infection). duration of action of *CNS diseases. metronidazole *CNS: *Severe renal disease. Neurotoxicological effect, .Enzyme Inducers *Severe hepatic disease. Insomnia, dizziness, Peripheral neuropathy, paresthesia (phenytoin and phenobarbitone). Encephalopathy, convulsion (IV infusion, rare). duration of action of metronidazole *Dysuria, dark urine. Metronidazole inhibits CYP-450 ( *Neutropenia. 2C9 & 3A4) so: *Disulfiram-like effect if taken -Increases anticoagulant effect of with alcohol.(next slide) warfarin. slide doctor’s note important explanation Disulfiram like-effect Combining metronidazole and alcohol causes nausea, vomiting, abdominal distress, flushing, headache, tachycardia, hyperventilation Alcohol Aldehyde dehydrogenase dehydrogenase ETHANOL Acetaldehyde Acetate Metronidazole inhibits this enzyme and this will lead to accumulation of acetaldehyde slide doctor’s note important explanation Tinidazole has similar activity to metronidazole but better potency* *the dose is less than metronidazole but is has the same action a simpler dosing regimen a better has longer toxicity profile duration of than action (12- metronidazole 14h) advantages slide doctor’s note important explanation 2. Emetine 3. Dehydroemetine ( Emetine is an alkaloid derived from ipeca while dehydroemetine is a synthetic 4. Chloroquine analog ). -Both are effective against tissue trophozoites of E.histolytica causing irreversible block of protein synthesis. -Anti-malarial drug M.O.A -Because of major toxicity concerns they have been almost completely replaced by metronidazole. -Have erratic oral absorption. -Given preferably subcutaneously but could be given by IM, NEVER I.V. Pharmacokinetics -Has long plasma half life about 5 days. ---------- -Metabolized & excreted slowly via kidney so they have a cumulative effect. -Should not be used for more than 10 days (usually 3-5 days). -Amoebic liver abscess. Used in combination with -Intestinal wall infections. metronidazole or Clinical Uses -Severe forms of amebiasis acute amoebic dysentery dehydroemetine for amebic dehydroemetine is preferable due to less toxicity (3-5 days(. liver diseases. -Dehydroemetine is less toxic than emetine. -GIT: nausea, vomiting, diarrhea. -pruritus is common -Serious toxicities: cardiotoxicity, Hypotension, cardiac -Nausea, vomiting, abdominal arrhythmias, heart failure. pain, anorexia. Adverse Effects -Blurring of vision. Caution: the drug should not be used in patients with -Hemolysis in G6PD deficient cardiac or renal disease, in young children,or in patients. pregnancy. slide doctor’s note important explanation B.Luminal amoebicides used to eradicate cysts of E histolytica after treatment of invasive disease. -Include: Diloxanide furoate , Iodoquinol, Paromomycin Paromomycin Sulphate -Antibiotic: Paromomycin , Tetracycline. -Effective only against luminal forms of ameba -Has direct amebicidal action (causes leakage by its action on cell membrane of M.O.A parasite(. -Indirect killing of bacterial flora essential for proliferation of pathogenic amoebae. -Aminoglycoside antibiotic. -Given orally -Not significantly absorbed from GIT Pharmacokinetics -Small amount absorbed is excreted unchanged in urine (may accumulate with renal Insufficiency*( . Clinical Uses -Use in chronic amebiasis to eliminate cysts (in cysts passers). -Gastrointestinal distress and diarrhea. Precautions Adverse Effects -*Severe renal disease -patients with GIT ulceration slide doctor’s note important explanation B.Luminal amoebicides Diloxanide furoate Iodoquinol -Mechanism of action is unknown -Mechanism of action is unknown. -Direct amoebicidal action against luminal forms. M.O.A -effective against the luminal forms of amebiasis= -Not active against trophozoites in intestinal asymptomatic wall or extra-intestinal tissues. -Ester of diloxanide + furoic acid . -Given orally. -Is given orally Pharmaco -It splits in the intestine liberating diloxanide -Poorly absorbed, -The unabsorbed diloxanide is the amoebicidal kinetics excreted in feces. agent. -The absorbed portion is excreted in urine. -Drug of choice for asymptomatic intestinal Clinical infection (cysts passers( . -to eradicate cysts of E histolytica after luminal amoebicide for asymptomatic amebiasis. Uses treatment of invasive disease with systemic amebicides. -GIT: Nausea, vomiting, diarrhea. -Peripheral neuropathy including optic neuritis. Adverse -Flatulence -Enlargement of the thyroid gland. Effects -Nausea, vomiting, abdominal cramps. -Iodine sensitivity. -interference with thyroid function tests (increase protein-bound serum iodine, decrease in measured (131I uptake). -Iodoquinol should be used with caution in patients with optic neuropathy, renal or thyroid disease. Contra - Pregnancy -discontinued if it produces persistent diarrhea or - Children(less than 2years( indications Signs of iodine toxicity(dermatitis, urticaria, pruritus, fever(. C.Bacillary dysentery -Fluoroquinolones such as ciprofloxacin. -Cotrimoxazole (trimethoprim- sulfamethoxazole). -Cotrimoxazole is commonly used in traveler’s diarrhea. -Children or patient
Load more

Recommended publications
  • Index Vol. 12-15
    353 INDEX VOL. 12-15 Die Stichworte des Sachregisters sind in der jeweiligen Sprache der einzelnen Beitrage aufgefiihrt. Les termes repris dans la Table des matieres sont donnes selon la langue dans laquelle l'ouvrage est ecrit. The references of the Subject Index are given in the language of the respective contribution. 14 AAG (Alpha-acid glycoprotein) 120 14 Adenosine 108 12 Abortion 151 12 Adenosine-phosphate 311 13 Abscisin 12, 46, 66 13 Adenosine-5'-phosphosulfate 148 14 Absorbierbarkeit 317 13 Adenosine triphosphate 358 14 Absorption 309, 350 15 S-Adenosylmethionine 261 13 Absorption of drugs 139 13 Adipaenin (Spasmolytin) 318 14 - 15 12 Adrenal atrophy 96 14 Absorptionsgeschwindigkeit 300, 306 14 - 163, 164 14 Absorptionsquote 324 13 Adrenal gland 362 14 ACAI (Anticorticocatabolic activity in­ 12 Adrenalin(e) 319 dex) 145 14 - 209, 210 12 Acalo 197 15 - 161 13 Aceclidine (3-Acetoxyquinuclidine) 307, 13 {i-Adrenergic blockers 119 308, 310, 311, 330, 332 13 Adrenergic-blocking activity 56 13 Acedapsone 193,195,197 14 O(-Adrenergic blocking drugs 36, 37, 43 13 Aceperone (Acetabutone) 121 14 {i-Adrenergic blocking drugs 38 12 Acepromazin (Plegizil) 200 14 Adrenergic drugs 90 15 Acetanilid 156 12 Adrenocorticosteroids 14, 30 15 Acetazolamide 219 12 Adrenocorticotropic hormone (ACTH) 13 Acetoacetyl-coenzyme A 258 16,30,155 12 Acetohexamide 16 14 - 149,153,163,165,167,171 15 1-Acetoxy-8-aminooctahydroindolizin 15 Adrenocorticotropin (ACTH) 216 (Slaframin) 168 14 Adrenosterone 153 13 4-Acetoxy-1-azabicyclo(3, 2, 2)-nonane 12 Adreson 252
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Cutaneous Amebiasis in Pediatrics
    OBSERVATION Cutaneous Amebiasis in Pediatrics Mario L. Magan˜a, MD; Jorge Ferna´ndez-Dı´ez, MD; Mario Magan˜a,MD Background: Cutaneous amebiasis (CA), which is still Conclusions: Cutaneous amebiasis always presents with a health problem in developing countries, is important painful ulcers. The ulcers are laden with amebae, which to diagnose based on its clinical and histopathologic are relatively easy to see microscopically with routine features. stains. Erythrophagocytosis is an unequivocal sign of CA. Amebae reach the skin via 2 mechanisms: direct and in- Observations: Retrospective medical record review of direct. Amebae are able to reach the skin if there is a lac- 26 patients with CA (22 adults and 4 children) treated from eration (port of entry) and if conditions in the patient 1955 to 2005 was performed. In addition to the age and are favorable. Amebae are able to destroy tissues by means sex of the patients, the case presentation, associated ill- of their physical activity, phagocytosis, enzymes, secre- ness or factors, and method of establishing the diagnosis, tagogues, and other molecules. clinical pictures and microscopic slides were also analyzed. Arch Dermatol. 2008;144(10):1369-1372 UTANEOUS AMEBIASIS (CA) ria, are opportunistic organisms that act as can be defined as damage pathogens, usually in the immunocompro- to the skin and underly- mised host, who can develop disease in any ing soft tissues by tropho- organ, such as the skin and central ner- zoites of Entamoeba histo- vous system. This kind of amebiasis has be- lytica, the only pathogenic form for humans. come more common during the last few C 8-18 Cutaneous amebiasis may be the only ex- years.
    [Show full text]
  • International Journal for Scientific Research & Development| Vol. 4, Issue 09, 2016 | ISSN (Online): 2321-0613
    IJSRD - International Journal for Scientific Research & Development| Vol. 4, Issue 09, 2016 | ISSN (online): 2321-0613 Study of Percentage Tinidazole in Different Brands of Antiprotozoal Tablets Contation Tinidazole Shiv Pratap Singh Dangi1 R.N. Shukla2 P.K. Sharma3 1Msc Student 2Professor & HOD 3Associated Professor 1,2,3Department of Applied Chemistry 1,2,3Samrat Ashok Technological Institute Vidisha (M.P.) 464001 [India] Abstract— Protozoal diseases particularly malaria, leishmaniasis and changes disease, are major cause of II. MATERIALS AND METHODS mortality in various tropical and subtropical regions. Where Antiprotozoal are drugs to treat infection cause by A. Collection of Samples: unicellular organisms that destroy protozoa or inhibit their I have collected four samples of different brands of growth and the ability to reproduce. Protozoal infection antiprotozoal tablets containing Tinidazole then desigenteted transmission can be person to person by infected water or as, TZ-1, TZ-2, TZ-3 and TZ-4. food, direct contact with a parasite, a mosquito or tick. B. Chemical and Reagents: Tinidazole is the most preferred choice of drug for intestinal amoebiasis. The aim of this study is to carry out the quality Methanol, Acetone, Dichloromethane and distilled water, all test of different brands of Tinidazole Tablets I analyzed solvents and reagents used were of analytical grade. various parameters such as identification, solubility and % assay to check the quality. All the tablets compared with III. METHODS authorized standard were found within the range. A. Description Key words: Tinidazole, Anti-protozoal, Amoebiasis, The description of each sample was performed as per the IP Protozoal disease, Anti-protozoal drug volume (III) 2007[10].
    [Show full text]
  • CRUX 71Sepoct2015
    VOLUME - XII ISSUE - LXXI SEP/OCT 2015 Amoebiasis, also known as amebiasis or entamobiasis, is an infection caused by any of the amoebas of the Entamoeba group. Symptoms are most common upon infection by Entamoeba histolytica. Amoebiasis can present with no, mild, or severe symptoms. Symptoms may include abdominal pain, mild diarrhoea, bloody diarrhea or severe colitis with tissue death and perforation. This last complication may cause peritonitis. People affected may develop anemia due to loss of 1 Editorial blood. Disease Invasion of the intestinal lining causes amoebic bloody diarrhea or amoebic colitis. If the parasite 2 reaches the bloodstream it can spread through the body, most frequently ending up in the liver Diagnosis where it causes amoebic liver abscesses. Liver abscesses can occur without previous diarrhea. Cysts of entamoeba can survive for up to a month in soil or for up to 45 minutes under fingernails. It 9 Trouble is important to differentiate between amoebiasis and bacterial colitis. The preferred diagnostic Shooting method it through faecal examination under microscope, but requires a skilled microscopist and may not be reliable when excluding infection. Increased white blood cell count is present in severe 10 Bouquet cases, but not in mild ones. The most accurate test is for antibodies in the blood, but it may remain positive following treatment. Prevention of amoebiasis is by separating food and water from faeces and by proper sanitation 11 Interpretation measures. There is no vaccine. There are two treatment options depending on the location of the infection. Amoebiasis in tissues is treated with either metronidazole, tinidazole, nitazoxanide, 12 Tulip News dehydroemetine or chloroquine, while luminal infection is treated with diloxanide furoate or iodoquinoline.
    [Show full text]
  • POISONS LIST APPENDIX Amoebicides: Carbarsone
    POISONS LIST APPENDIX Amoebicides: Carbarsone Clioquinol and other halogenated hydroxyquinoline compounds Dehydroemetine; its salts Diloxanide; its compounds Dimetridazole Emetine Ipronidazole Metronidazole Pentamidine; its salts Ronidazole Anaesthetics: Alphadolone acetate Alphaxolone Desflurane Disoprofol Enflurane Ethyl ether Etomidate; its salts Halothane Isoflurane Ketamine; its salts Local anaesthetics, the following: their salts; their homologues and analogues; their molecular compounds Amino-alcohols esterified with benzoic acid, phenylacetic acid, phenylpropionic acid, cinnamic acid or the derivatives of these acids; their salts Benzocaine Bupivacaine Butyl aminobenzoate Cinchocaine Diperodon Etidocaine Levobupivacaine Lignocaine Mepivacaine Orthocaine Oxethazaine Phenacaine Phenodianisyl Prilocaine Ropivacaine Phencyclidine; its salts Propanidid Sevoflurane Tiletamine; its salts Tribromoethanol Analeptics and Central Stimulants: Amiphenazole; its salts Amphetamine (DD) Bemegride Cathine Cathinone (DD) Dimethoxybromoamphetamine (DOB) (DD) 2, 5-Dimethoxyamphetamine (DMA) (DD) 2, 5-Dimethoxy-4-ethylamphetamine (DOET) (DD) Ethamivan N-Ethylamphetamine; its salts N-Ethyl MDA (DD) N-Hydroxy MDA (DD) Etryptamine (DD) Fencamfamine Fenetylline Lefetamine or SPA or (-)-1-dimethylamino-1, 2-diphenylethane Leptazol Lobelia, alkaloids of Meclofenoxate; its salts Methamphetamine (DD) Methcathinone (DD) 5-Methoxy-3, 4-methylenedioxyamphetamine (MMDA) (DD) Methylenedioxyamphetamine (MDA) (DD) 3, 4-Methylenedioxymetamphetamine (MDMA) (DD) Methylphenidate;
    [Show full text]
  • Short Reports Metronidazole in Treatment of Children with Amoebic Liver Abscess
    Arch Dis Child: first published as 10.1136/adc.48.11.911 on 1 November 1973. Downloaded from Short reports Archives of Disease in Childhood, 1973, 48, 911. Metronidazole in treatment of multiple abscesses which were not accessible by needle aspiration. All recovered but were given children with amoebic liver dehydroemetine during the postoperative period. abscess No relapses were observed during a 3-month follow-up. We have shown that metronidazole combined with dehydroemetine is an effective treatment of Discussion children with amoebic liver abscess and that the The results of this trial are similar to those former drug has advantages over chloroquine obtained in our previous study of metronidazole (Scragg and Powell, 1970). In adults, metro- combined with dehydroemetine in which 11 of 15 nidazole in the absence of other drug therapy is children were cured, 2 more required surgical extremely effective in curing amoebic liver abscess drainage, and 2 died (Scragg and Powell, 1970). and remains the best of the nitroimidazole We have indicated that age is a most important derivatives that we have investigated (Powell, 1972; factor in prognosis and that, regardless of the nature Powell and Elsdon-Dew, 1972). However, in the ofthe therapy, mortality is higher in infants and very very young we have been reluctant to abandon young children (Scragg and Powell, 1968). In the parenteral emetine preparations owing to the present study the average age of our patients was severity of the condition in this age group. Never- significantly lower than in our previous trials, hence theless, the highly satisfactory results that we have the efficacy of metronidazole alone was put to a obtained with metronidazole alone in hundreds of rigorous test.
    [Show full text]
  • Appendix I. Therapeutic Recommendations (Reprinted from the Medical Letter) the Medical Letter® on Drugs and Therapeutics
    Appendix I. Therapeutic Recommendations (Reprinted from The Medical Letter) The Medical Letter® On Drugs and Therapeutics Published by The Medical Letter, Inc .• 1000 Main Street, New Rochelle, NY. 10801 • A Nonprofit Publication Vol. 35 (Issue 911) December 10, 1993 DRUGS FOR PARASITIC INFECTIONS Parasitic infections are found throughout the world. With increasing travel, immigration, use of immunosuppressive drugs, and the spread of AIDS, physicians anywhere may see infections caused by previously unfamiliar parasites. The table below lists first-choice and alternative drugs for most parasitic infections. Adverse effects of antiparasitic drugs are listed on page 120. For information on the safety of antiparasitic drugs in pregnancy, see The Medical Letter Handbook of Antimicrobial Therapy, 1992, page 151. DRUGS FOR TREATMENT OF PARASITIC INFECTIONS Infection Drug Adult Dosage* Pediatric Dosage* AMEBIASIS (Entamoeba histolytica) a.ymptomatlc Drug of choice: lodoquinol' 650 mg tid x 20d 30-40 mg/kg/d in 3 doses x 20d OR Paromomycin 25-30 mg/kg/d in 3 doses x 7d 25-30 mg/kg/d in 3 doses x 7d Alternative: Diloxanide furoate' 500 mg tid x 10d 20 mg/kg/d in 3 doses x 10d mild to mod.rat. Int•• tlnal dl••••• Drugs of choice:3 Metronidazole 750 mg tid x 10d 35-50 mg/kg/d in 3 doses x 10d OR Tinidazole' 2 grams/d x 3d 50 mg/kg (max. 2 grams) qd x 3d s.v.r. Int•• tlnal dis.as. Drugs of choice:3 Metronidazole 750 mg tid x 10d 35-50 mg/kg/d in 3 doses x 10d OR Tinidazole' 600 mg bid x 5d 50 mg/kg (max.
    [Show full text]
  • Hepatic Amebiasis: Experience in the Therapy of 56 Cases*
    .4(1.4 AIH) l’ORJ.S,,pp/ 2. 303. 19111 HEPATIC AMEBIASIS: EXPERIENCE IN THE THERAPY OF 56 CASES* Ireneu Cruz and F. J. Z. Carneiro Chaves Serviço 2. Medicina. Hospital de Curry Cabral. Lisboa.Serviço de Terapêutica Médica (Medicina 11). Faculdade de Medicina. Hospital de S. João. Porto. SUMMARY The resulta of therapy in 56 consecutive cases of hepatic amebiasis are reviewed. In retrospecr, the resulta in patients receiving metronidazole alone, dehydroemetine combined with chioroquine, and dehydroemetine combined with chloroquine and metronidazole were compared. No deaths occured. Our resulta confirm the great efficacy of metronidazole alone. The response to treatment was similar in patients receiving dehydroemetine combined with chloroquine but the average number of days of hospitalization was greater in these patients. No advantage was demonstrated for rhe combination of metronidazole with dehydroe metine and chioroquine. In retrospect these patients proved to have a more severe and protracted course with more frequent surgical complications and a greater need for closed aspiration of the abscess. Closed aspiration, not used routinely, has not reduced the number of days of hospitaliza tion. Significant side effects were not observed. Arnebicidai drug therapy has dramatically changed the prognosis of hepatic ame biasis, nowadays a readily curable disease (Poweli, 1971). Enduring landmarks in the development of drug therapy were the introduction of emetine hydrochloride (Rodgers, 1912), foliowed by chloroquine (Conan, 1948) and later by metronidazole (Powell et ai, 1966). The efficacy of these drugs, in single or combined drug regimens has been weli proved (Powell, 1971; Adams and MacLeod, 1977). The purpose of the present study is to review in retrospect our experience with three drug regimens in 56 consecutive cases of hepatic amebiasis.
    [Show full text]
  • AMEBIASIS [Amebic Dysentery, Amebiosis]
    AMEBIASIS [Amebic Dysentery, Amebiosis] SPECIES: Nonhuman primates primary laboratory risk AGENT: Entamoeba histolytica. RESERVOIR AND INCIDENCE: The reservoir of E. histolytica is man. The infections is present worldwide but is most prevalent and severe in tropical areas, where rates may exceed 40% under conditions of crowding, poor sanitation, and poor nutrition. It is estimated that there are about 50 million case of invasive amebiasis and 40,000- 100,000 deaths annually worldwide. In temperate areas, however, amebiasis tends to be asymptomatic or a mild, chronic infection that often remains undiagnosed. In the USA, seropositive rates up to 2-5% have been reported in some populations. Reported incidence of 0-31% in the feces of clinically normal Rhesus monkeys, 2-67% in Chimps, and up to 30% in other NHP. TRANSMISSION: Transmission may be by ingestion of infective cysts, contaminated water or food, by flies, or fomites. Resistant cysts or more fragile trophozoites CYSTS are the INFECTIOUS form found in the stool of asymptomatic carriers or patients with mild disease. The cysts remain viable, if moist and cool for 12 days. They remain viable for 30 days in water. Laboratory animal personnel are usually infected from fecal matter transferred to the skin or clothing. DISEASE IN ANIMALS: In dogs, infection by E. histolytica is generally asymptomatic and frequently localized in the cecum. Occasionally, it can invade tissues and cause acute or chronic amebiasis. Rhesus monkeys are generally resistant and usually experience asymptomatic infection, but chronic, mild colitis can occur. In chimpanzees, the infection can persist for a long time, in most cases subclinically, but sometimes it invades the tissues causing ulcerative colitis and hepatic abscesses.
    [Show full text]
  • Cutaneous Amebiasis: 50 Years of Experience
    Cutaneous Amebiasis: 50 Years of Experience Jorge Fernández-Díez, MD; Mario Magaña, MD; Mario L. Magaña, MD Although cutaneous amebiasis (CA) is a rare of skin and subcutaneous tissues. Therefore, CA disease, it is a public health concern worldwide, is a particularly virulent form of amebiasis. particularly in developing nations. It gains impor- Cutis. 2012;90:310-314. tance because of its severe clinical course, which can be confused with other disorders. Therefore, knowledge of its clinical features, histopathology, utaneous amebiasis (CA) can be charac- and pathogenesis is essential. We present a retro- terized as injury to the skin and underly- spective analysis over 50 years of 26 patients with ing soft tissues by trophozoites of Entamoeba C 1,2 CA who were diagnosed and treated at 2 Mexican histolytica. Other species of the genus such as institutions. Our main focus was to draw clinical Entamoeba hartmanni, Entamoeba coli, Entamoeba information to identify mechanisms by which ame- gingivalis,3 and Entamoeba dispar4 are considered bae reach the skin, occurring in a relatively small nonpathogenic. Entamoeba dispar has now been rec- percentage of infected individuals. The recorded ognized as responsible for many cases of amebiasis data included age and sex ofCUTIS the patients, form of in patients who were previously considered “healthy presentation, any associated illnesses and/or fac- carriers.” It is morphologically indistinguishable from tors, and methods for diagnosis. Histologic slides E histolytica but genetically and serologically dif- were reviewed in all cases; cytologic preparations ferent.5,6 Entamoeba moshkovskii is morphologically also were available for 6 cases. Most patients indistinguishable from E histolytica and E dispar but were male (overall male to female ratio, 1.9 to 1).
    [Show full text]